Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor
Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
About this trial
This is an interventional treatment trial for Untreated Childhood Medulloblastoma
Eligibility Criteria
Inclusion Criteria: Histologically confirmed primary medulloblastoma or posterior fossa primitive neuroectodermal tumor Prior definitive tumor resection within 6 weeks of study No evidence of metastases Hemoglobin at least 10 g/dL Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 AST less than 2.5 times normal Bilirubin less than 1.5 mg/dL Creatinine less than 1.2 mg/dL Creatinine clearance greater than 70 mL/min No prior chemotherapy No prior radiotherapy See Disease Characteristics
Sites / Locations
- Children's Oncology Group
Arms of the Study
Arm 1
Other
Chemotherapy, surgery, radiation therapy
Patients receive induction chemotherapy consisting of vincristine sulfate IV on days 1, 8, and 15; cisplatin IV over 6 hours on day 1; cyclophosphamide IV over 30 minutes on day 2; and oral etoposide daily on days 2-22. Treatment repeats every 28 days for a total of 4 courses. After completion of induction chemotherapy, patients with residual disease undergo a therapeutic conventional surgery (second resection). Within 4 weeks after completion of induction chemotherapy or second resection, patients receive 3-dimensional conformal radiation therapy daily, 5 days a week, for 6 weeks. Four weeks after completion of 3-dimensional conformal radiation therapy, patients receive alternating treatments of maintenance chemotherapy. Patients receive vincristine sulfate IV on days 1, 8, and 15 and cyclophosphamide IV over 30 minutes on day 1 of courses 1, 3, 5, and 7 and oral etoposide daily on days 1-21 of courses 2, 4, 6, and 8. Treatment continues every 28 days for 8 courses.